TCEAL1

Across TCGA pan-cancer cohorts, TCEAL1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TCEAL1’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where TCEAL1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TCEAL1 is over-expressed in tumor, although a few such as PDAC and LSCC show the opposite, repressed pattern.

PDAC, LSCC, and HNSC are the cancer types where TCEAL1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCEAL1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	II,III,IV	−0.384	<.001	9	view →
LSCC	Female	All	−0.326	<.001	7	view →
HNSC	All	III,IV	+0.150	.021	4	view →
CCRCC	Male	II,III,IV	−0.119	.019	3	view →
OV	All	All	−0.862	.009	2	view →
LUAD	All	All	+0.102	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TCEAL1–PDAC

Open the PDAC breakdown →